{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:57:18Z","timestamp":1771268238858,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Achieving minimal residual disease (MRD) negativity following treatment for multiple myeloma (MM) is associated with improved progression free and overall survival. In the UK, MRD assessments in MM are not incorporated into routine clinical use outside trials. Widely used in other haematological malignancies, there is a role for widening the availability of myeloma MRD assays to laboratories outside larger treating centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We set up and assessed concordance of a multicolor flow cytometry (MCF) assay for MM MRD in collaboration with a reference center including validity following delayed processing of samples using an optimized fixation step. We then conducted a real\u2010world snapshot of MRD results in a cohort of newly diagnosed transplant\u2010eligible patients treated with UK standard induction therapies at the time of analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>43 MCF MRD samples run in parallel with a reference center showed high correlation and minimal bias. 24 samples were split and processed in duplicate both fixed and fresh, with strong correlation, minimal bias, and no change in plasma cell phenotype by flow markers confirming a 6\u2010day delay in processing did not affect assay performance. A real\u2010world snapshot found 17% (10\/58) of patients were MRD\u2010negative post\u2010bortezomib\u2010based triplet induction therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We successfully adopted a reference MCF MM MRD method which was stable for up to 6\u2009days following sample collection potentially allowing broader access of this assay to smaller laboratories which would facilitate further investigation of the prognostic value and clinical utility of MRD assessments outside the trial setting in real\u2010world practice.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.22100","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T16:00:19Z","timestamp":1668268819000},"page":"304-310","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for <scp>real\u2010world<\/scp> practice"],"prefix":"10.1002","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0624-165X","authenticated-orcid":false,"given":"Annabel","family":"McMillan","sequence":"first","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"},{"name":"Department of Haematology Whittington Health NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thien\u2010An","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Haematology Geneva University Hospital  Geneve Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Galas\u2010Filipowicz","sequence":"additional","affiliation":[{"name":"Cancer Institute University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marquita","family":"Camilleri","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lecat","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Ainley","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Guo","sequence":"additional","affiliation":[{"name":"Cancer Institute University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"},{"name":"Cancer Institute University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Sive","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8017"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21971"},{"key":"e_1_2_6_6_1","first-page":"401","article-title":"Double autologous stem cell transplantation significantly prolongs progression\u2010free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: An analysis of phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo M.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17148"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01012-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02228"},{"key":"e_1_2_6_10_1","volume-title":"Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable 2022","author":"Excellence NIfHaC","year":"2022"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_6_12_1","volume-title":"Minimal residual disease for plasma cell myeloma by flow cytometry (Pilot \u2010not accredited)","author":"Immunophenotyping UNfL","year":"2022"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12789"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.02.003"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00377-0"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8533"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.267831"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370460"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0297"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21271"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.176"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.22100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:58:47Z","timestamp":1692683927000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.22100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/cyto.b.22100"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.22100","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}